CUPR

Company Overview — What Does Cuprina Holdings (Cayman) LTD Do?

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future. As of June 30, 2024, we manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement. In addition to our currently commercialized MEDIFLY products, we have two lines of chronic wound care products in our pipeline. Such lines of pipeline chronic wound care products include: . Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus); and . Products utilizing medical leeches for wound treatment. We currently expect development of such products to take place over the course of 2025 and 2026 and to become commercially available subject to regulatory approval. However, we may not be able to successfully develop the aforementioned pipeline products on the timeline currently envisioned, or at all, and even if we do, these products may not receive the necessary regulatory approvals from the authorities in the intended markets where we plan to introduce them. We believe what sets us apart is our focus on developing functionally specific chronic wound care products designed to address the major stages of wound healing process, from chronic to closure. Our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline, are poised to benefit from escalating global market demand. This demand is primarily fueled by the demographic shift towards an aging population and the concurrent rise in comorbidities such as diabetes, obesity, cardiovascular ailments, and peripheral vascular diseases. We either self-develop our chronic wound care products or co-develop them through technology licensing agreements or research collaboration with a renowned research university. In June 2022, we were granted an exclusive license from NTUitive Pte. Ltd., a wholly owned subsidiary of Nanyang Technological University, to develop and commercialize a range of chronic wound care products using collagen derived from bullfrog skin. In addition, in August 2022, we entered into an industry research collaboration agreement with Nanyang Technological University, or, together with its subsidiaries, NTU, pursuant to which both parties agreed to jointly undertake a research project regarding the development and validation of bullfrog skin waste to generate collagen-based wound care products. We have been selling our MEDIFLY products primarily in Singapore since February 2020. In March 2023, our MEDIFLY products became commercially available in Hong Kong. Looking ahead, we have strategic plans in place for 2025 and 2026 to expand our sales and establish physical operations in several key regions, including the Middle East (in particular, the member states of the Gulf Cooperation Council, or GCC), and mainland China. These expansion initiatives will further enable us to cater to the growing demand for our products in these promising markets, cementing our position as a trusted player in the field of chronic wound care and treatment. For our cosmeceuticals business, we introduced three products in 2023, including a hydrating balm product, a muscle energy cream and a pain relief muscle patch. For our currently commercialized cosmeceutical products, we have commissioned original equipment manufacturers of skincare products to develop the formulation and manufacture the substantially finished and finished products. In addition, we plan to explore the possibility of developing a range of potential cosmeceutical product candidates incorporating bullfrog collagen with a view to making them commercially available between 2025 and 2028, subject to the progress of the relevant R&D work. We offer our chronic wound care products to both public and private hospitals and clinics, where patients can obtain them through prescription from a physician. Our customers primarily include major public and private hospitals and clinics in Singapore. Our commercialized cosmeceutical products can be purchased directly by individual customers through a variety of channels, including retailers and gyms in Singapore and other countries such as Malaysia and Australia, as well as online shopping platforms such as Shopee. Our commitment to quality is demonstrated by our attainment of ISO 13485:2016 standards for Quality Management Systems and Manufacturing Processes and Controls for our manufacturing facility located in Singapore in 2020. We are working towards obtaining compliance with 21 CFR Part 820, an integral component of the Current Good Manufacturing Practice, or CGMP, regulations, to secure FDA 510(k) clearance for our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline. Our principal executive office is in Singapore. Cuprina Holdings (Cayman) LTD (CUPR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Yong Qi David Quek and employs approximately 14 people. With a market capitalization of $7M, CUPR is one of the notable companies in the Healthcare sector.

Cuprina Holdings (Cayman) LTD (CUPR) Stock Rating — Reduce (April 2026)

As of April 2026, Cuprina Holdings (Cayman) LTD receives a Reduce rating with a composite score of 31.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CUPR ranks #3,383 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cuprina Holdings (Cayman) LTD ranks #516 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CUPR Stock Price and 52-Week Range

Cuprina Holdings (Cayman) LTD (CUPR) currently trades at $0.37. The stock gained $0.01 (3.8%) in the most recent trading session. Recent trading volume was 370K shares, suggesting relatively thin trading activity.

Is CUPR Overvalued or Undervalued? — Valuation Analysis

Cuprina Holdings (Cayman) LTD (CUPR) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 91.20x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cuprina Holdings (Cayman) LTD trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cuprina Holdings (Cayman) LTD Profitability — ROE, Margins, and Quality Score

Cuprina Holdings (Cayman) LTD (CUPR) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -357.7% versus the sector average of -33.1%.

On a margin basis, Cuprina Holdings (Cayman) LTD reports gross margins of -6.3%, compared to 71.5% for the sector. The operating margin is -3404.8% (sector: -66.1%). Net profit margin stands at -3229.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CUPR Debt, Balance Sheet, and Financial Health

Balance sheet data for CUPR is evaluated through our stability factor. Total debt on the balance sheet is $160,283. Cash and equivalents stand at $85,253.

CUPR has a beta of 0.42, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Cuprina Holdings (Cayman) LTD is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cuprina Holdings (Cayman) LTD Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cuprina Holdings (Cayman) LTD reported revenue of $35,369 and earnings per share (EPS) of $-4.67. Net income for the quarter was $-1M. Gross margin was -6.3%. Operating income came in at $-1M.

In FY 2024, Cuprina Holdings (Cayman) LTD reported revenue of $35,369 and earnings per share (EPS) of $-4.67. Net income for the quarter was $-1M. Gross margin was -6.3%. Revenue grew -53.7% year-over-year compared to FY 2023. Operating income came in at $-1M.

In FY 2023, Cuprina Holdings (Cayman) LTD reported revenue of $76,384 and earnings per share (EPS) of $-4.71. Net income for the quarter was $-848,598. Gross margin was 36.3%. Operating income came in at $-809,770.

CUPR Dividend Yield and Income Analysis

Cuprina Holdings (Cayman) LTD (CUPR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CUPR Momentum and Technical Analysis Profile

Cuprina Holdings (Cayman) LTD (CUPR) has a momentum factor score of 16/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.

CUPR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cuprina Holdings (Cayman) LTD (CUPR) ranks #516 out of 838 stocks based on the Blank Capital composite score. This places CUPR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CUPR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CUPR vs S&P 500 (SPY) comparison to assess how Cuprina Holdings (Cayman) LTD stacks up against the broader market across all factor dimensions.

CUPR Next Earnings Date

No upcoming earnings date has been announced for Cuprina Holdings (Cayman) LTD (CUPR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CUPR? — Investment Thesis Summary

The quantitative profile for Cuprina Holdings (Cayman) LTD suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Momentum is weak at 16/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, Cuprina Holdings (Cayman) LTD (CUPR) earns a Reduce rating with a composite score of 31.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CUPR stock.

Related Resources for CUPR Investors

Explore more research and tools: CUPR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CUPR head-to-head with peers: CUPR vs AZN, CUPR vs SLGL, CUPR vs VMD.